Today, people and organizations who want to raise awareness and funds for chronic diseases, such as breast cancer, have a number of creative and highly engaging options to choose from: art exhibits, red carpet events, marathons, etc. This month, Living Essentials LLC, a Michigan-based distributor of vitamin-enriched energy drinks, is bringing back its own way to support breast cancer patients and research.
Living Essentials’ 5-Hour Energy shots will come in a limited edition, specially-marked pink lemonade variant beginning this month. For every bottle sold, 5 cents will go t Living Beyond Breast Cancer (LBBC), a national education and support organization with programs like a toll-free help hotline, conferences, webinars, publications, podcasts and small grants.
The company’s commitment to breast cancer and LBBC is now in its second year, with a predicted minimum donation of $200,000 at the end of the campaign. Last year, the company donated $344,269.20 to the LBBC along with national exposure, giving the organization a significant boost in their many services and future plans. In fact, thanks to Living Essentials’ contributions, calls to LBBC’s hotline doubled, over 41,000 copies of Guides to Understanding Breast Cancer were distributed, and LBBC.org received more than 200,000 site visits.
LBBC’s associate director of marketing and corporate partnerships, Kevin Gianotto, said that Living Essentials’ 5-hour ENERGY® campaign helped millions of people discover the organization and either get the help they need, give assistance to others, or both. The partnership has been integral to the fulfillment of their vision to help breast cancer patients and loved ones cope better through emotional support and information dissemination.
In other breast cancer news, the National Heart, Lung and Blood Institute (NHLBI) and National Cancer Institute (NCI) granted the Wake Forest Baptist Medical Center a total of $4.4 million worth of funding for a clinical trial on the efficacy of atorvastatin for the prevention of cardiotoxicity in patients with breast cancer.